Practice Alert

Preventing RSV in children and adults: A vaccine update

Author and Disclosure Information

In addition to 3 vaccines, there’s also a new monoclonal antibody for prevention of respiratory syncytial virus. Learn how each can be used in infants and children, adults, and pregnant people.


 

References

In the past year, there has been significant progress in the availability of interventions to prevent respiratory syncytial virus (RSV) and its complications. Four products have been approved by the US Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). They include 2 vaccines for adults ages 60 years and older, a monoclonal antibody for infants and high-risk children, and a maternal vaccine to prevent RSV infection in newborns.

Who’s at increased risk for severe RSV disease?

RSV in adults

While there is some uncertainty about the total burden of RSV in adults in the United States, the CDC estimates that each year it causes 0.9 to 1.4 million medical encounters, 60,000 to 160,000 hospitalizations, and 6000 to 10,000 deaths.1 The rate of RSV-caused hospitalization increases with age,2 and the infection is more severe in those with certain chronic medical conditions (TABLE 11). The FIGURE2 demonstrates the outcomes of adults who are hospitalized for RSV. Adults older than 65 years have a 5% mortality rate if hospitalized for RSV infection.2

Outcomes among adults hospitalized for RSV, 2017-2018 to 2019-2020

Vaccine options for adults

Two vaccines were recently approved for the prevention of RSV-associated lower respiratory tract disease (LRTD) in those ages 60 years and older: RSVPreF3 (Arexvy, GSK), which is an adjuvanted recombinant F protein vaccine, and RSVpreF (Abrysvo, Pfizer), which is a recombinant stabilized vaccine. Both require only a single dose (0.5 mL IM), which provides protection for 2 years.

The efficacy of the GSK vaccine in preventing laboratory-confirmed, RSV-­associated LRTD was 82.6% during the first RSV season and 56.1% during the second season. The efficacy of the Pfizer vaccine in preventing symptomatic, laboratory-confirmed LRTD was 88.9% during the first RSV season and 78.6% during the second season.1 However, the trials leading to licensure of both vaccines were underpowered to show efficacy in the oldest adults and those who are frail or to show efficacy against RSV-caused hospitalization.

Safety of the adult RSV vaccines. The safety trials for both vaccines had a total of 38,177 participants. There were a total of 6 neurologic inflammatory conditions that developed within 42 days of vaccination, including 2 cases of suspected Guillain-Barré syndrome (GBS), 2 cases of possible acute disseminated encephalomyelitis, and 1 case each of chronic inflammatory demyelinating polyneuropathy and undifferentiated motor-­sensory axonal polyneuropathy.1 That is a rate of 1 case of a neurologic inflammatory condition for every 6363 people vaccinated. Since the trials were not powered to determine whether the small number of cases were due to chance, postmarketing surveillance will be needed to clarify the true risk for GBS or other neurologic inflammatory events from RSV vaccination.

The lack of efficacy data for the most vulnerable older adults and the lingering questions about safety prompted the ACIP to recommend that adults ages 60 years and older may receive a single dose of RSV vaccine, using shared clinical decision-­making—which is different from a routine or risk-based vaccine recommendation. For RSV vaccination, the decision to vaccinate should be based on a risk/benefit discussion between the clinician and the patient. Those most likely to benefit from the vaccine are listed in ­TABLE 1.1

While data on coadministration of RSV vaccines with other adult vaccines are sparse, the ACIP states that co-administration with other vaccines is acceptable.1 It is not known yet whether boosters will be needed after 2 years.

Continue to: RSV in infants and children

Pages

Recommended Reading

Maternal pertussis vax effective for infants in most vulnerable months
MDedge Family Medicine
ACIP updates recommendations for influenza vaccination
MDedge Family Medicine
52-year-old man • intermittent fevers • recently received second dose of COVID-19 vaccine • tremors in all 4 extremities • Dx?
MDedge Family Medicine
New RSV vaccine will cut hospitalizations, study shows
MDedge Family Medicine
New meningococcal vaccine wins FDA approval
MDedge Family Medicine
How clinicians can prepare for and defend against social media attacks
MDedge Family Medicine
mRNA vaccine cuts COVID-related Guillain-Barré risk
MDedge Family Medicine
Serious mental illness tied to 50% higher all-cause mortality risk after COVID
MDedge Family Medicine
FDA to health care providers: Double-check COVID vaccine dose for children
MDedge Family Medicine
Keep COVID-19 vaccination on your patients’ radar
MDedge Family Medicine